<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165555</url>
  </required_header>
  <id_info>
    <org_study_id>99-124</org_study_id>
    <nct_id>NCT00165555</nct_id>
  </id_info>
  <brief_title>Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma</brief_title>
  <official_title>Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulfate in the Multimodality Treatment of Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to determine the safety and maximally tolerated dose (MTD) of&#xD;
      cisplatin administered in the operating room and put into the chest and abdomen for one hour.&#xD;
      We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees&#xD;
      celsius.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will undergo surgery with pleurectomy/decortication which entails the removal&#xD;
           of the inner and outer skin of the lung, including the pleura overlying the pericardium&#xD;
           and diaphragm. Resection of the pericardium and diaphragm are occasionally necessary to&#xD;
           debulk the tumor. This surgery is part of standard care for pleural mesothelioma.&#xD;
&#xD;
        -  After surgery, a one hour lavage with heated cisplatin will be administered to the&#xD;
           hemithorax (and abdominal regions if the diaphragm is no longer present). The lung&#xD;
           itself is not removed, only the diseased portion of the lung and surrounding areas with&#xD;
           tumor.&#xD;
&#xD;
        -  Immediately following the one-hour lavage, a six hour infusion of sodium thiosulfate&#xD;
           will begin to help reduce the side effects of the cisplatin.&#xD;
&#xD;
        -  Patients will remain hospitalized until they have recovered from surgery (usually 7-14&#xD;
           days).&#xD;
&#xD;
        -  Patients will return to the hospital three months after their surgery to have fluid&#xD;
           drawn from their chest via an ultrasound guided thoracentesis. This is called a saline&#xD;
           wash.&#xD;
&#xD;
        -  Patients will be in the study actively for three months. This includes a 2-week and&#xD;
           4-week post-operative follow-up in which blood work is performed. As well as a 3-month&#xD;
           follow-up for the saline wash. Long-term follow-up includes computed tomography of the&#xD;
           chest and abdomen every 6 months to assess recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximally tolerated dose of intracavitary cisplatin in patients with malignant pleural mesothelioma,</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To quantitate the safety of intraoperative intrathoracic/intraperitoneal hyperthermic cisplatin</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to study the pharmacokinetics of cisplatin administered in this way.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <condition>Malignant Pleural Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given as a heated one-hour lavage to the hemithorax after surgery.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Given intravenously over 6 hours after the cisplatin lavage.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologic confirmation of malignant pleural mesothelioma&#xD;
&#xD;
          -  Patients who are able to tolerate surgical cytoreduction but unable to undergo&#xD;
             extrapleural pneumonectomy due to poor cardiopulmonary reserve or tumor invasion&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Malignancy is confined to the affected hemithorax.&#xD;
&#xD;
          -  Grossly normal cardiac function with an EKG showing no cardiomyopathy or acute changes&#xD;
&#xD;
          -  Evidence of adequate renal and hepatic function&#xD;
&#xD;
          -  Karnofsky performance status of 70% or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extended disease outside the ipsilateral hemithorax as determined radiologically and&#xD;
             intraoperatively&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Non-malignant systemic disease&#xD;
&#xD;
          -  Active concomitant malignancy&#xD;
&#xD;
          -  Psychiatric or addictive disorders which would preclude obtaining informed consent&#xD;
&#xD;
          -  Prior treatment within the last 2 months, other than surgical resection for their&#xD;
             current malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Sugarbaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cisplatin</keyword>
  <keyword>pleurectomy</keyword>
  <keyword>decortication</keyword>
  <keyword>heated cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

